Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

News

Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Receives FDA Fast Track Designation for Development of PH10 to Treat Major Depressive Disorder


Vistagen (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system

Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Laboratories Adds Craig B. Thompson, M.D. to Board of Directors


Charles River Laboratories International, Inc. (NYSE: CRL) today announced the re-appointment of Craig B. Thompson, M.D., former President and Chief Executive Officer, Memorial Sloan-Kettering

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
Sartorius Stedim Biotech SA: DECLARATION RELATIVE TO THE NUMBER OF SHARES AND VOTING RIGHTS MAKING UP THE ISSUED CAPITAL
EQS-News: Sernova Announces CEO Succession Plan and Expanded Management Team
EQS-News: Sernova Announces CEO Succession Plan and Expanded Management Team
EQS-News: Sernova Announces CEO Succession Plan and Expanded Management Team
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Proteasehttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease


Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191106005906/en/305625/5/puma_logo_JPEG.jpg
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)


Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on December 3, 2022, the Compensation Committee of Puma’s Board of Directors approved the grant of inducement

Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4): https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Reports New Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the course of autoimmune disease, announced that

Humana CEO recognized as one of Modern Healthcare’s 100 Most Influential People in Healthcare: http://s3-eu-west-1.amazonaws.com/sharewise-dev/attachment/file/24514/Humana_logo.png
Humana CEO recognized as one of Modern Healthcare’s 100 Most Influential People in Healthcare


Humana Inc. (NYSE: HUM) is proud to announce that Bruce D. Broussard, President and Chief Executive Officer, is recognized by Modern Healthcare as one of the 100 Most Influential People in

Agilent Opens Customer Experience Center Highlighting Genomics and Diagnostics Solutions:
Agilent Opens Customer Experience Center Highlighting Genomics and Diagnostics Solutions


Agilent Technologies Inc. (NYSE: A) today announced the opening of a new Customer Experience Center (CEC) in Lexington, MA, focused on solutions from Agilent genomics and diagnostics product

Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Sensorion Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting in San Francisco: https://mms.businesswire.com/media/20210609005851/en/705797/5/logo-sensorion2.jpg
Sensorion Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting in San Francisco


Regulatory News:



Sensorion (FR0012596468 – ALSEN) a pioneering clinical-stage biotechnology company, specialising in the development of novel therapies to restore, treat and prevent within the

Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Sonova completes acquisition of the HYSOUND Group, expanding direct consumer access in China
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Form 8.3 - The Vanguard Group, Inc.: Mediclinic International plc
Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Dayhttp://www.flickr.com/photos/w0ahitslo/6955091156/sizes/z/in/photostream/: All rights reserved by Queen Beuaroo
Pfizer Invites Public to Register for Webcast of Pfizer Near-Term Launches + High-Value Pipeline Day


Pfizer Inc. (NYSE: PFE) invites investors and the general public to access a live video webcast of its Near-Term Launches + High-Value Pipeline Day on Monday, December 12, 2022 from 1:00 p.m. EST

IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease: https://mms.businesswire.com/media/20221201005288/en/772499/5/IGC_Logo.jpg
IGC Commences Phase 2 Clinical Trials Evaluating Drug Candidate IGC-AD1 for the Treatment of Agitation in Dementia From Alzheimer’s Disease


India Globalization Capital, Inc. (NYSE American: IGC) (“IGC” or the “Company”), announced that it has begun “A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-Controlled, Trial of the

Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection: https://mms.businesswire.com/media/20191106005189/en/754630/5/charles_river_logo.jpg
Charles River Launches Endosafe Nexus 200, Emphasizes Critical Importance of Smart Automation for Endotoxin Detection


Charles River Laboratories International, Inc. (NYSE: CRL) launches the Endosafe® Nexus 200™, expanding its robust endotoxin testing portfolio. The Nexus 200 is the next evolution of Charles

Navidea Biopharmaceuticals Files Appeal in CRG Case: https://mms.businesswire.com/media/20191107006076/en/389794/5/navidea_cmyk.jpg
Navidea Biopharmaceuticals Files Appeal in CRG Case


Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today

Maple Heights Behavioral Health Hosts Ceremony to Celebrate Grand Opening: https://mms.businesswire.com/media/20200504005676/en/583255/5/ACHC.jpg
Maple Heights Behavioral Health Hosts Ceremony to Celebrate Grand Opening


Acadia Healthcare Company, Inc. (NASDAQ: ACHC) today announced its newest operating joint venture hospital, Maple Heights Behavioral Health, located in Fort Wayne, Indiana, and held a ribbon-tying

Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis: https://mms.businesswire.com/media/20191107005278/en/707846/5/Aurinia-logo-web-700px.jpg
Aurinia Announces the Great Britain Marketing Authorization of LUPKYNIS® (voclosporin) for the Treatment of Lupus Nephritis


Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (Aurinia or the Company), a biopharmaceutical company committed to delivering therapeutics that change the trajectory of autoimmune disease, announced

QuidelOrtho to Host Investor Day on December 13, 2022: https://s24.q4cdn.com/594651504/files/design/QO_Logo_FINAL.png
QuidelOrtho to Host Investor Day on December 13, 2022


QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion

Truckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Truckers’ Health Adaptative Technology (T.H.A.T.) Study Evaluates the Impact of Digital Virtual Models of Care on the Health and Wellbeing of Professional Truck Drivers


Dexcom, Inc. (NASDAQ: DXCM), - November is National Diabetes Awareness Month, time to bring attention to the prevalence and risk of diabetes within our diverse Canadian population, and to profile

LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting: https://mms.businesswire.com/media/20191101005329/en/555341/5/LN-Logo-Main-PANTONE.jpg
LivaNova to Present Scientific Data at American Epilepsy Society 2022 Annual Meeting


LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology and innovation company, today announced its participation in the American Epilepsy Society (AES) 2022 Annual Meeting, taking place

Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder: https://mms.businesswire.com/media/20220908005443/en/1564398/5/Vistagen_Primary-Logo_Blue.jpg
Vistagen Receives FDA “Study May Proceed” Letter Under its Investigational New Drug Application for PH10 to Treat Major Depressive Disorder


Vistagen, (NASDAQ: VTGN) a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression and other central nervous system